We determined the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an affected area in northern Iran in April 2020. Antibodies to SARS-CoV-2 were detected in 528 persons by using rapid tests. Adjusted prevalence of SARS-CoV-2 seropositivity was 22.2% (95% CI 16.4%–28.5%).
All Keywords
【저자키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, Seroprevalence, asymptomatic infections, Iran, Guilan, 【초록키워드】 coronavirus, Seroprevalence, severe acute respiratory syndrome Coronavirus, Prevalence, Seropositivity, respiratory, Rapid tests, acute respiratory syndrome, 95% CI, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, affected,
【저자키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, Seroprevalence, asymptomatic infections, Iran, Guilan, 【초록키워드】 coronavirus, Seroprevalence, severe acute respiratory syndrome Coronavirus, Prevalence, Seropositivity, respiratory, Rapid tests, acute respiratory syndrome, 95% CI, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, affected,
2020년 4월 이란 북부 지역에서 중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2)의 혈청유병률을 확인했습니다. 신속검사를 통해 528명에게서 SARS-CoV-2 항체가 검출되었습니다. SARS-CoV-2 혈청 양성의 조정된 유병률은 22.2%(95% CI 16.4%–28.5%)였습니다.